Comparative analysis between RQ-PCR and digital-droplet-PCR of immunoglobulin/T-cell receptor gene rearrangements to monitor minimal residual disease in acute lymphoblastic leukaemia

被引:64
作者
Della Starza, Irene [1 ]
Nunes, Vittorio [1 ]
Cavalli, Marzia [1 ]
De Novi, Lucia Anna [1 ]
Ilari, Caterina [1 ]
Apicella, Valerio [1 ]
Vitale, Antonella [1 ]
Testi, Anna Maria [1 ]
Del Giudice, Ilaria [1 ]
Chiaretti, Sabina [1 ]
Foa, Robin [1 ]
Guarini, Anna [1 ]
机构
[1] Sapienza Univ Rome, Dept Cellular Biotechnol & Haematol, Rome, Italy
关键词
quantitative PCR; ALL; MRD; gene rearrangement; TIME QUANTITATIVE PCR; DNA COPY NUMBER; CLINICAL-SIGNIFICANCE; ABSOLUTE QUANTIFICATION; CONCERTED ACTION; RISK; CHILDHOOD; CLASSIFICATION; TRANSCRIPT; MRD;
D O I
10.1111/bjh.14082
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Real-time quantitative polymerase chain reaction (RQ-PCR) is a standardized tool for minimal residual disease (MRD) monitoring in acute lymphoblastic leukaemia (ALL). The applicability of this technology is limited by the need of a standard curve based on diagnostic DNA. The digital droplet PCR (ddPCR) technology has been recently applied to various medical fields, but its use in MRD monitoring is under investigation. In this study, we analysed 50 ALL cases by both methods in two phases: in the first, we established analytical parameters to investigate the applicability of this new technique; in the second, we analysed MRD levels in 141 follow-up (FU) samples to investigate the possible use of ddPCR for MRD monitoring in ALL patients. We documented that ddPCR has sensitivity and accuracy at least comparable to those of RQ-PCR. Overall, the two methods gave concordant results in 124 of the 141 analysed MRD samples (88%, P = 0.94). Discordant results were found in 12% borderline cases. The results obtained prove that ddPCR is a reliable method for MRD monitoring in ALL, with the advantage of quantifying without the need of the calibration curves. Its application in a cohort of patients with a longer FU will conclusively define its clinical predictive value.
引用
收藏
页码:541 / 549
页数:9
相关论文
共 38 条
[1]   Absolute quantification of the pretreatment PML-RARA transcript defines the relapse risk in acute promyelocytic leukemia [J].
Albano, Francesco ;
Zagaria, Antonella ;
Anelli, Luisa ;
Coccaro, Nicoletta ;
Tota, Giuseppina ;
Brunetti, Claudia ;
Minervini, Crescenzio Francesco ;
Impera, Luciana ;
Minervini, Angela ;
Cellamare, Angelo ;
Orsini, Paola ;
Cumbo, Cosimo ;
Casieri, Paola ;
Specchia, Giorgina .
ONCOTARGET, 2015, 6 (15) :13269-13277
[2]   Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL) [J].
Bassan, Renato ;
Spinelli, Orietta ;
Oldani, Elena ;
Intermesoli, Tamara ;
Tosi, Manuela ;
Peruta, Barbara ;
Rossi, Giuseppe ;
Borlenghi, Erika ;
Pogliani, Enrico M. ;
Terruzzi, Elisabetta ;
Fabris, Pietro ;
Cassibba, Vincenzo ;
Lambertenghi-Deliliers, Giorgio ;
Cortelezzi, Agostino ;
Bosi, Alberto ;
Gianfaldoni, Giacomo ;
Ciceri, Fabio ;
Bernardi, Massimo ;
Gallamini, Andrea ;
Mattei, Daniele ;
Di Bona, Eros ;
Romani, Claudio ;
Scattolin, Anna Maria ;
Barbui, Tiziano ;
Rambaldi, Alessandro .
BLOOD, 2009, 113 (18) :4153-4162
[3]   PROPOSALS FOR CLASSIFICATION OF ACUTE LEUKEMIAS [J].
BENNETT, JM ;
CATOVSKY, D ;
DANIEL, MT ;
FLANDRIN, G ;
GALTON, DAG ;
GRALNICK, HR ;
SULTAN, C .
BRITISH JOURNAL OF HAEMATOLOGY, 1976, 33 (04) :451-&
[4]   Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study [J].
Borowitz, Michael J. ;
Devidas, Meenakshi ;
Hunger, Stephen P. ;
Bowman, W. Paul ;
Carroll, Andrew J. ;
Carroll, William L. ;
Linda, Stephen ;
Martin, Paul L. ;
Pullen, D. Jeanette ;
Viswanatha, David ;
Willman, Cheryl L. ;
Winick, Naomi ;
Camitta, Bruce M. .
BLOOD, 2008, 111 (12) :5477-5485
[5]   Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia [J].
Brüggemann, M ;
Raff, T ;
Flohr, T ;
Gökbuget, N ;
Nakao, M ;
Droese, J ;
Lüschen, S ;
Pott, C ;
Ritgen, M ;
Scheuring, U ;
Horst, HA ;
Thiel, E ;
Hoelzer, D ;
Bartram, CR ;
Kneba, M .
BLOOD, 2006, 107 (03) :1116-1123
[6]   Improved assessment of minimal residual disease in B cell malignancies using fluorogenic consensus probes for real-time quantitative PCR [J].
Brüggemann, M ;
Droese, J ;
Bolz, I ;
Lüth, P ;
Pott, C ;
von Neuhoff, N ;
Scheuering, U ;
Kneba, M .
LEUKEMIA, 2000, 14 (08) :1419-1425
[7]   DETECTION OF MINIMAL RESIDUAL DISEASE IN ACUTE-LEUKEMIA - METHODOLOGIC ADVANCES AND CLINICAL-SIGNIFICANCE [J].
CAMPANA, D ;
PUI, CH .
BLOOD, 1995, 85 (06) :1416-1434
[8]  
Cazzaniga G, 2005, HAEMATOLOGICA, V90, P382
[9]   Defining the correct role of minimal residual disease tests in the management of acute lymphoblastic leukaemia [J].
Cazzaniga, Giovanni ;
Valsecchi, Maria Grazia ;
Gaipa, Giuseppe ;
Conter, Valentino ;
Biondi, Andrea .
BRITISH JOURNAL OF HAEMATOLOGY, 2011, 155 (01) :45-52
[10]   Digital quantification of mutant DNA in cancer patients [J].
Diehl, Frank ;
Diaz, Luis A., Jr. .
CURRENT OPINION IN ONCOLOGY, 2007, 19 (01) :36-42